SUBSCRIBE

Breaking News on Supplements, Health & Nutrition - Europe US edition | APAC edition

News > Research

Read more breaking news

 

 

Melatonin may reduce risk of certain breast cancers: Study

By Nathan Gray+

11-Feb-2014
Last updated on 11-Feb-2014 at 13:42 GMT2014-02-11T13:42:00Z

Melatonin may reduce risk of certain breast cancers: Study

Melatonin may have the potential to reduce the risk of certain breast cancers by slowing the growth of tumours, according to a new early stage study.

Writing in PLoS One, the early stage research suggests that the hormone melatonin - which is also approved for use as a nutritional supplement in some areas - could reduce the risk of developing certain types of cancer by blocking the growth of tumours and new blood vessels that support tumour growth.

Led by Adarsh Shankar and his colleagues from Henry Ford Hospital in Detroit, USA, and the Foundation for Research Support of the State of São Paulo, Brazil, the team noted that melatonin's suspected antioxidant properties, have led some to believe it may suppress the growth of certain types of cancer cells - especially when combined with certain anti-cancer drugs.

"These early stage research results with the melatonin drug in a triple-negative breast cancer animal models achieved in our lab has not been seen anywhere else," said Shankar.

"The key finding of the study is that we now know that we can trace this ... and its effect on tumour growth, which opens the door for more research on this topic."

Study details

To determine the effectiveness of melatonin at reducing tumour growth, the team evaluated the action of melatonin on angiogenesis in ER-negative breast cancer in vitro and in vivo using cell and mouse models respectively.

Mice were randomly assigned to either melatonin or control groups. The melatonin group received supplementation each night for 21 days, with melatonin administered at pharmacologic concentrations one hour before room lighting was switched off.

At the end of the 21-day study, researchers used single photon emission computed tomography (SPECT) to determine whether the melatonin had effectively decreased the size of implanted human triple negative breast cancer in the mouse models - and if there was any sign of  changes in the formation of new blood vessels.

Additionally, tumour volume was measured each week and tumour tissue was analyzed at the end of treatment.

Shankar and his colleagues revealed that none of the mice given melatonin showed any loss of weight and lethargy during the 21-day treatment; instead, most showed excessive movement but no irritability or aggressive behaviour.

Those recieving melatonin also showed significantly smaller tumours after 21 days while the mean tumour volume increased significantly in the control group. In addition, there was less vascular growth in the tumours of the melatonin group.

Shankar and his team concluded that their results suggest that melatonin has the potential as a therapeutic agent for breast cancer, and may reduce the risk of cancer development.

However, they cautioned that the research is still in its very early stages and results are not yet ready to be translated in to humans.

Source: PLoS One
Published online ahead of print, doi: 10.1371/journal.pone.0085311
"Effect of Melatonin on Tumor Growth and Angiogenesis in Xenograft Model of Breast Cancer"
Authors: Bruna Victorasso Jardim-Perassi, Ali S. Arbab

Live Supplier Webinars

Polyphenols tipped to become the way to innovate in Sports Nutrition
Fytexia
Orally bioavailable standardized botanical derivatives in sport nutrition: special focus on recovery in post-intense physical activities
Indena
Collagen in motion: move freely and keep your injuries in check
Leading manufacturer of gelatine and collagen peptides
Life’s too short for slow proteins. Whey proteins hydrolysates: Fast delivery for enhanced performance
Arla Foods Ingredients
What it Takes to Compete and Win in Today’s Sports Nutrition Market
Capsugel
Sports Nutrition Snapshot: Key regional drivers and delivery format innovations
William Reed Business Media
Gutsy performance: How can microbiome modulation help athletes and weekend warriors
William Reed Business Media
Pushing the boundaries: Where’s the line between ‘cutting edge nutrition’ and doping
William Reed Business Media
Alpha & Omega in Sports Nutrition – Using Omega 3’s and A-GPC to improve performance and recovery.
KD Pharma

On demand Supplier Webinars

High-amylose maize starch may reduce the risk of type 2 diabetes: what does this qualified health claim mean?
Ingredion
Balancing Innovation and Risk in Sports Nutrition Ingredients
NSF-International
Explaining bio-hacking: is there a marketing opportunity for food companies?
William Reed Business Media
Personalized Nutrition – how an industry can take part in shaping the future of Nutrition
BASF Nutrition & Health
Find out Nutritional and ingredient lifecycle solutions and strategies!
Roquette
Is the time rIpe for I-nutrition?
William Reed Business Media
The Advantage of Outsourcing Fermentation-based Manufacturing Processes
Evonik Health Care
All supplier webinars